Results 131 to 140 of about 15,740 (203)

The Natural Quassinoid Brusatol Enhances Venetoclax Efficacy and Overcomes Resistance in Myeloid Leukemias

Cancer Science, Volume 117, Issue 8, Page 2274-2288, August 2026.
Schematic illustration of the mechanisms by which the natural quassinoid brusatol induces apoptosis in myeloid leukemias and enhances venetoclax efficacy via p53‐dependent apoptosis and mitochondrial dysfunction. ABSTRACT While venetoclax‐based combinations have shown promising results in acute myeloid leukemia (AML), the remission duration is ...
Shin‐ichiro Kawaguchi, Kazuya Sato, Junko Izawa, Norihito Takayama, Hiroko Hayakawa, Ken Suzaki, Susumu Goyama, Chiyoko Kato, Eiji Sakashita, Kaoru Tominaga, Hitoshi Endo, Yoshinobu Kanda   +11 more
wiley   +1 more source

Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia. [PDF]

J Am Heart Assoc
Selvakumar S, Shetty S, Sharma AB, Zahra FT, Wang E, Koelmeyer H, Carver J, Fradley MG, Jung W, Ky B, Lefebvre B, Scherrer-Crosbie M, Wilcox NS, Wu KY, Chan O, Xie Z, Kuykendall AT, Sallman DA, Padron E, Alomar M, Cleveland JL, Mo Q, Komrokji R, Lancet JE, Yun S, Lee DH.   +25 more
europepmc   +1 more source

Transition Into Clinical Routine and Survival Outcomes of BCL2‐ and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry

European Journal of Haematology, Volume 117, Issue 2, Page 351-357, August 2026.
ABSTRACT Within a dataset of the German CLL Study Group (GCLLSG) registry, 274 patients were allocated to a cohort with venetoclax and 888 to a cohort with BTKi (79 acalabrutinib, 809 ibrutinib), each as first administered targeted substance class within the documented treatment sequence.
Nadine Kutsch, Rudy Ligtvoet, Sandra Robrecht, Hartmut Linde, Thomas Illmer, Steffen Dörfel, Jörg Lipke, Ali Aldaoud, Rudolf Schlag, Jolanta Dengler, Othman Al‐Sawaf, Petra Langerbeins, Paula Cramer, Michael Hallek, Barbara Eichhorst, Kirsten Fischer, Anna Fink   +16 more
wiley   +1 more source

Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy. [PDF]

Blood
Kennedy VE, Peretz CAC, Walia A, Chyla B, Sun Y, Hill JE, Tran E, Koh AD, Ferng TT, Pintar S, Jones M, Popescu B, Lomeli I, Chehab F, Murad N, John A, Roy RP, Olshen AB, Berryhill CA, Davis C, Angus SP, Rivera JM, Meshulam A, Stieglitz E, Joshi SK, Traer E, Dail M, Hamidi H, Altman JK, Daver NG, Levis MJ, McCloskey J, Perl AE, Smith CC.   +33 more
europepmc   +1 more source

First‐Line Treatment of IGHV‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens

European Journal of Haematology, Volume 117, Issue 2, Page 375-383, August 2026.
ABSTRACT Immunoglobulin heavy chain variable region‐unmutated (IGHV‐U) chronic lymphocytic leukemia (CLL) represents a biologically aggressive subgroup with limited responsiveness to chemoimmunotherapy (CIT). To clarify the comparative effectiveness of available frontline options, we conducted a comprehensive Bayesian network meta‐analysis of ...
Santino Caserta, Enrica Antonia Martino, Danilo Lofaro, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Fortunato Morabito, Valter Gattei, Massimo Gentile   +13 more
wiley   +1 more source

Durable MRD-Negative Remission With Blinatumomab and Venetoclax in Heavily Pretreated Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. [PDF]

EJHaem
Qadir MS, Farooq S, Jamy O.
europepmc   +1 more source

Outcomes of patients with de novo and secondary acute myeloid leukaemia treated with front‐line hypomethylating agents and venetoclax: A retrospective Italian study

British Journal of Haematology, Volume 209, Issue 2, Page 799-803, August 2026.
Ilaria Tanasi, Edoardo Tamellini, Elena Marchetti, Eleonora De Bellis, Cristina Ancora, Francesco Angotzi, Davide Facchinelli, Francesca Capraro, Giulia Battaglia, Alessandra Sperotto, Michele Gottardi, Matteo Leoncin, Mauro Krampera, Mario Tiribelli, Carmela Gurrieri   +14 more
wiley   +1 more source

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management

European Journal of Haematology, Volume 117, Issue 2, Page 305-319, August 2026.
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Mamdouh Skafi, Valter Gattei, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Breaking through the azacitidine plateau?-venetoclax in high-risk myelodysplastic syndrome. [PDF]

Ann Transl Med
An Y, Karantanos T.
europepmc   +1 more source

A proposed refined definition of acute myeloid leukaemia patients ineligible for intensive therapy: The Integrated Comorbidity–ECOG–Age criteria

British Journal of Haematology, Volume 209, Issue 2, Page 809-811, August 2026.
Daniel Weidl, Myrto Boukovala, Doris Glaser, Bettina Barthel, Lars Bullinger, Michael Heuser   +5 more
wiley   +1 more source